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and Massimo Cristofanilli1,2*
Abstract
Introduction: Epidermal growth factor receptor (EGFR) overexpression has been associated with prognostic and
predictive value in inflammatory breast cancer (IBC). Epidermal growth factor receptor 2 (HER2) overexpression is
observed at a higher rate in IBC compared with noninflammatory breast cancer. Current clinically available anti-
HER2 therapies are effective only in patients with HER2 amplified breast cancer, including IBC. AZD8931 is a novel
small-molecule equipotent inhibitor of EGFR, HER2, and HER3 signaling. In this study, we investigated the antitumor
activity of AZD8931 alone or in combination with paclitaxel using preclinical models of EGFR-overexpressed and
HER2 non-amplified IBC cells.
Methods: Two IBC cell lines SUM149 and FC-IBC-02 derived from pleural effusion of an IBC patient were used in this
study. Cell growth and apoptotic cell death were examined in vitro. For the in vivo tumor growth studies, IBC cells were
orthotopically transplanted into the mammary fat pads of immunodeficient mice. AZD8931 was given by daily oral
gavage at doses of 25 mg/kg, 5 days/week for 4 weeks. Paclitaxel was subcutaneously injected twice weekly.
Results: AZD8931 significantly suppressed cell growth of IBC cells and induced apoptosis of human IBC cells in vitro.
Significantly, we showed that AZD8931 monotherapy inhibited xenograft growth and the combination of paclitaxel +
AZD8931 was demonstrably more effective than paclitaxel or AZD8931 alone treatment at delaying tumor growth
in vivo in orthotopic IBC models.
Conclusion: AZD8931 single agent and in combination with paclitaxel demonstrated signal inhibition and antitumor
activity in EGFR-overexpressed and HER2 non-amplified IBC models. These results suggest that AZD8931 may provide a
novel therapeutic strategy for the treatment of IBC patients with HER2 non-amplified tumors.
Keywords: Inflammatory breast cancer, EGFR, HER2, HER3, AZD8931, Paclitaxel
Introduction
Inflammatory breast cancer (IBC) is a rare and highly
metastatic variant of breast cancer with the poorest sur-
vival of all types of breast cancer [1,2]. IBC has shown
the capacity to spread early, primarily through lymphatic
channels and secondarily through blood vessels causing
the typical inflammatory clinical signs. Characteristic clin-
ical symptoms are rapid onset and progression of breast
enlargement with overlying skin changes, such as diffuse
erythema, edema or peau d’orange, tenderness, hardening,
and warmth; a tumor mass may or may not be present
[3,4]. IBC primarily affects younger women under the age
of 50 at diagnosis, and is difficult to be detected as most
patients do not present with a lump, but rather occurs as
tumor emboli. At the time of diagnosis, most patients
have lymph node metastases, and 30% of the patients have
distal metastases including brain, bones, visceral organs
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and soft tissue with variable frequency, in contrast to 5%
of patients with non-IBC [5]. The lower survival rate of
IBC patients may be due to the highly metastatic nature
of the disease [6].
Primary treatment of patients with IBC is typically
multimodal involving neoadjuvant combination chemo-
therapy followed by surgery, adjuvant chemotherapy, or
radiotherapy [5]. The HER family has an important role
in driving breast cancer. Epidermal growth factor recep-
tor (EGFR) overexpression has been demonstrated as
prognostic factors in IBC. Overexpression of epidermal
growth factor receptor 2 (HER2) occurs during the stage
of advanced tumor but whether the overexpression has a
prognostic role in IBC has yet to be established [7,8].
Anti-HER2 therapies have shown benefit in IBC patients
with HER2 amplification, which accounts for approxi-
mately 40% of IBC [9]. However, therapeutic options for
patients with ER-negative and HER2 non-amplified IBC
are very limited. IBCs are predominantly basal-like or
triple-negative (TN) as characterized by the estrogen
receptor (ER)-negative, progesterone receptor (PgR)-
negative and HER2 non-amplified status [10]. EGFR is
overexpressed in 30% of IBCs and 50% of TNIBCs
[2,11]. IBC patients with EGFR-positive tumors have a
lower overall survival rate than patients with EGFR-
negative tumors, and EGFR overexpression in IBC is fre-
quently associated with an increased risk of recurrence
[9]. EGFR overexpression is also correlated with large
tumor size, aggressiveness and poor prognosis [12,13].
Thus, EGFR could be a potential therapeutic target in IBC
and, in particular, in patients with EGFR-overexpressed
IBC that currently has very limited treatment options.
Currently there are few human IBC cell lines available
for studying this complex disease. Although available cell
lines were derived from IBC patients, the molecular sig-
natures among IBC cell lines are very distinct. SUM149
was developed from the primary tumor of IBC patient,
but in vivo xenograft model are unable to recapitulate
the tumor emboli that are the signature of IBC in
humans. We have recently developed a new IBC cell
line, FC-IBC-02 that was derived from the pleural effu-
sion fluid of a woman with secondary metastatic IBC
[14,15]. FC-IBC-02 cells form tumor spheroids in sus-
pension culture, a characteristic of cancer stem cells,
and recapitulate the tumor emboli in vivo xenograft
models. SUM149 and FC-IBC-02 could be different rep-
resentative models for studying the biology of IBC, both
SUM149 and FC-IBC-02 cell lines are basal-like and ER/
Pgr(−), EGFR-overexpressed and HER2 non-amplified.
AZD8931 was developed with the hypothesis that com-
bined inhibition of EGFR, HER2, and HER3-mediated sig-
naling may be more effective for clinical cancer treatment
[16]. Pharmacological profiling has shown that AZD8931
is a novel, equipotent, reversible small-molecule ATP
competitive inhibitor of EGFR, HER2, and HER3 signal-
ing. Previous results showed that AZD8931 was signifi-
cantly more potent against EGFR, HER2 and HER3
signaling than other EGFR inhibitors such as lapatinib or
gefitinib in vitro. AZD8931 has shown greater antitumor
activity in a range of xenografted models compared with
lapatinib or gefitinib [16]. In the present study, we exam-
ined the effects of AZD8931 on cell growth and apoptotic
cell death of human IBC cells in vitro. Further, we investi-
gated the antitumor activity of AZD8931 alone or in com-
bination with paclitaxel in EGFR-overexpressed and HER2
non-amplified IBC models.
Methods and materials
Reagents and cell culture
AZD8931 was synthesized and generously provided by
AstraZeneca [16]. SUM149 were obtained from Dr. Stephen
Ethier (Kramanos Institute, MI, USA) and are commer-
cially available (Asterand, Detroit, MI). SUM149 cells were
cultured in Ham’s F-12 media supplemented with 10%
fetal bovine serum (FBS), 1 μg/ml hydrocortisone, 5 μg/ml
insulin and antibiotic-antimycotic. The FC-IBC-02 tumor
cells were derived from primary human breast cancer cells
isolated from pleural effusion of an IBC patient [14,15].
Human samples used in this study were acquired with ap-
proval of the Fox Chase Cancer Center’s Institutional Re-
view Board. Importantly, written informed consent was
obtained from each participant. FC-IBC-02 cells were cul-
tured in DMEM/F12 media with 10% FBS and 1% L-glu-
tamine and antibiotic-antimycotic.
Antibodies and immunoblot
Following treatment with AZD8931 at the indicated con-
centration and time points, immunoblotting was per-
formed as previously described [15]. In brief, cells were
lysed in 1× lysis buffer (Cell signaling), and then the super-
natant was collected by centrifuging at 10,000 rpm for
10 min at 4°C. Protein concentration was determined
using the BCA protein assay reagent kit (Pierce, Rockford,
IL). Equal amounts of protein from cell lysates were re-
solved by SDS-PAGE electrophoresis. The membranes
were incubated at 4°C overnight with the following anti-
bodies: mouse anti-EGFR (1:1000; Cell Signaling), rabbit
anti-AKT and rabbit anti-phospho-AKT (1:1000; Cell Sig-
naling), mouse anti-β-actin (1:5,000; Santa Cruz). After in-
cubation with anti-mouse IgG horseradish peroxidase
conjugated secondary antibody (1:5,000; Amersham Phar-
macia Biotech), immunoreactive proteins were visualized
by the enhanced chemiluminescence reagents.
Cell proliferation and apoptotic assay
SUM149 and FC-IBC-02 cells (2 × 103) were seeded in
triplicate in a 96-well plate and cultured overnight. Cells
were treated with AZD8931 at indicated concentration
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for 72 hrs. Cell proliferation was monitored at the indi-
cated times, absorbance at 490 nm was measured using
a microplate reader using the MTS assay (CellTiter 96
AQueous One Solution cell proliferation assay, Pro-
mega) according to the manufacturer’s instruction.
Apoptotic cells were measured by Annexin V staining.
Cells (1 × 105) were treated with 1 μM AZD8931 for 48
and 72 hrs. Cells were harvested and labeled with
Annexin V-PE and 7-amino-actinomycin D (7-AAD)
(Guava Technologies Inc, Burlingame, CA) according to
the manufacturer’s instructions. The samples were then
analyzed by Guava system on a GuavaPC personal flow
cytometer (Guava Technologies).
In vivo xenograft studies
The protocol was approved by FCCC institutional ani-
mal care and use committee (IACUC). SUM149 and FC-
IBC-02 (3 × 106) cells were suspended in 200 μL of 1:1
ratio of phosphate-buffered saline/matrigel (BD Biosci-
ences) and orthotopically injected into the mammary fat
pads of six week old female C.B-17 severe combined im-
munodeficient (SCID) mice. Tumor volume was calcu-
lated from the formula TV = L*W*H*0.5236 where L, W,
and H are the tumor dimensions in three perpendicular
dimensions by caliper measurement. When tumor vol-
umes were approximately 50 mm3 for SUM149 cells or
80 mm3 for FC-IBC-02 cells, the mice were randomly al-
located into four groups (5 mice per group) and treat-
ments were initiated. AZD8931 was suspended in a 1%
(v/v) solution of polyoxyethylenesorbitan monooleate
(Tween 80) in deionized water and given once daily by
oral gavage at 25 mg/kg for 4 weeks. Paclitaxel solution
was diluted in saline and given twice weekly by subcutane-
ously injection at 10 mg/kg. The control-group received
1% Tween 80 vehicle treatment. Mice were sacrificed at
33 days (SUM149) or 26 days (FC-IBC-02) post treat-
ments. Tumors were surgically removed and weighed.
VeraTag analysis and immunohistochemical staining
Formalin fixed paraffin embedded sections of tumors
from control animals were subjected to VeraTag™ ana-
lysis. A pair of antibodies, one conjugated to biotin and
the other to a fluorescent molecule (VeraTag) suitable
for analysis by capillary electrophoresis, bind to distinct
epitopes on HER2, HER3 or PI3K. The VeraTag mole-
cules are attached to the antibodies via photo-cleavable
linkers. Methylene blue, conjugated to streptavidin,
binds to the biotin-labeled antibody and is photo-
activated by red-light. The released singlet oxygen, as a
result of methylene blue catalyzed photosensitization,
cleaves VeraTag molecules in close proximity to the
antibody-biotin-streptavidin complex.
Tumor-bearing mice were treated with AZD8931 at
50 mg/kg/day for 4 days. Tumors were removed and
fixed at 4 hrs after fourth dose. Formalin-fixed paraffin-
embedded tumors were cut onto glass slides and
processed for immunohistochemical (IHC) staining as
previously described [16]. In brief, antigen retrieval was
performed on formalin-fixed, paraffin-embedded tumor
sections and the following primary antibodies were used:
total EGFR (DAKO PharmDx), total HER2 (DAKO
Herceptest), total HER3 (CST clone D43D4), phospho-
EGFR (Epitomics #1139-1), phospho-HER2 (CST #2243),
phospho-HER3 (CST #4791), A polymer detection system
(DAKO Envision + K4007) was used for secondary detec-
tion and sections were counterstained with Carazzi’s
hematoxylin. Semiquantitative scoring was carried out by
light microscopy by a pathologist (CW) for immunohisto-
chemical brown staining on a four point scale (0+, none;
1+, weak; 2+, moderate; 3+, strong) and for percentage
(%) distribution, to calculate an H-Score (sum of 1 x% 1+,
2 x% 2+, and 3 x% 3+). Cytoplasmic and membrane stain-
ing was recorded.
Statistical analysis
Quantitative data were expressed as mean ± SD. Analysis
of variance (ANOVA) with Student’s t test was used to
determine the significant differences among experimen-
tal groups, and P < 0.05 was considered significant.
Results
IBC xenografted tumors express low HER2 and low to
medium HER3 levels
Both SUM149 and FC-IBC-02 overexpress EGFR and
are HER2 non-amplified. However, the relative levels of
HER2 and HER3 in these cell lines compared with other
breast cancer cell lines were not known. We measured
total HER2 and HER3 proteins, HER2-HER3 heterodi-
mer and HER3-PI3K complex levels in xenografted
tumor samples from SUM149 and FC-IBC-02 cells using
the sensitive and quantitative VeraTag™ technology.
When compared with samples from other breast cancer
cell lines, total HER2 and HER2-HER3 heterodimers
were expressed at low levels in both models (Figure 1A
and C). Total HER3 and HER3-PI3K complexes were
expressed at low levels in SUM149 xenografts and
medium levels in FC-IBC-02 xenografts (Figure 1B and
D). On the basis of these results, we conclude that IBC
xenografted tumors express relatively low levels of total
HER2 and HER2-HER3 heterodimers while the expression
of HER3 and HER3-PI3K complexes is more variable
across models, with the FC-IBC-02 model expressing
moderate levels of these two complexes.
AZD8931 inhibits EGFR pathway activity
Previous study showed that AZD8931 is an equipotent,
reversible inhibitor of EGFR, HER2 and HER3 signaling
with potent in vitro inhibition of EGFR, HER2 and
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HER3 phosphorylation in breast cancer and squamous
carcinoma cells [16]. As SUM149 and FC-IBC-02 cells
express a high level of EGFR and low levels of HER2
and HER3, we sought to determine the effects of
AZD8931 on the protein expression of EGFR and down-
stream markers. We tested the effects of AZD8931 on
EGFR, phospho-Akt. in SUM149 cells at different time
points. Western blot analysis showed that AZD8931 had
no significant effect on EGFR expression level, and
significantly inhibited phosphorylation of Akt in a time-
dependent manner (Figure 2A). The inhibition of phospho-
Akt was dose-dependent in both SUM149 and FC-IBC-02
cells (Figure 2B).
AZD8931 inhibits proliferation and induces apoptosis in
human IBC cells
As previous study has shown that AZD8931 exposure
results in significant inhibition of cell proliferation in
squamous cell carcinoma of the head and neck and
non–small cell lung carcinoma cell lines [16], we next
sought to determine the effects of AZD8931 on IBC cell
proliferation using the MTS assay. AZD8931 significantly
suppressed the proliferation of SUM149 cells in a dose-
dependent manner when compared with the control
(Figure 3A). Similar suppression of proliferation by
AZD8931 was observed for FC-IBC-02 cells (Figure 3B),
suggesting that the observed effects were not cell line spe-
cific. Based on these results, we conclude that AZD8931
suppresses human IBC cell proliferation in vitro.
We next examined early apoptotic cell death by
Annexin V staining. The percentage of apoptotic cell death
was significantly higher when SUM149 and FC-IBC-02
cells were treated with AZD8931 at both 48 and 72 hrs
(P < 0.001; Figure 3C and D), compared with controls.
AZD8931 inhibits the tumor growth of human IBC models
Previous study has shown that AZD8931 inhibits human
tumor xenograft growth with different sensitivities to
V
er
aT
ag
 H
ER
2T
0
50
100
150
200
250
300
350
400
450
500
550
600 Total HER2
0
2
4
6
8
10
12
14
16
18 Total HER3
V
er
aT
a
g
H
ER
3T
0
5
10
15
20
25
30 HER2-HER3 heterodimer
V
er
aT
ag
H
ER
2-
H
ER
3D
0
2
4
6
8
10
12
14
16
18
V
er
a
Ta
g
H
ER
3:
PI
3K
HER3:PI3K complex
A B
C D
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agents targeting either EGFR or HER2 in a variety of
models including one human breast cancer cell line BT-
474, which expresses ER/PgR, high levels of HER2, and
moderate levels of EGFR [16]. Here, we determine the
effects of AZD8931 alone or combined with paclitaxel
on the growth of human IBC cells in vivo in SCID mice.
Toward this goal, the tumors were orthotopically grown
in the mammary fat pads of SCID mice and monitored
by caliper measurement twice weekly. The changes
in tumor volume following different treatments for
both SUM149 and FC-IBC-02 cell lines are shown in
Figure 4A and C. The tumor growth curves represent
the group mean values over the course of 33 days for
SUM149 xenograft and 26 days for FC-IBC-02 xeno-
graft. AZD8931 alone significantly suppressed the xeno-
grafted tumor growth of SUM149 (P = 0.002; Figure 4A)
and FC-IBC-02 (P < 0.001; Figure 4C) cells compared
with the control group. The dose of AZD8931 at 25 mg/
kg was chosen based on previous study [16]. Paclitaxel
alone also delayed tumor growth over treatment com-
pared with the control group in both xenografted human
IBC models, but the effect of inhibition was much less
than that seen in the AZD8931 alone group. The com-
bination of paclitaxel + AZD8931 was more effective at
delaying tumor growth than the control and other treat-
ment groups in both xenografted IBC models. The dif-
ference was significant for paclitaxel + AZD8931 versus
paclitaxel alone in SUM149 (P = 0.01; Figure 4A) and
FC-IBC-02 (P < 0.01; Figure 4C). However, the difference
was not statistically significant compared with AZD8931
alone.
In addition, we also examined the weight of xeno-
grafted tumors at the end of study. The inhibitory pat-
tern of tumor size following different treatments was
very similar to that seen in tumor growth curves in both
IBC models. The combination of paclitaxel + AZD8931
was more effective at reducing tumor sizes than all of the
other treatment groups. The difference was also signifi-
cant for paclitaxel + AZD8931 versus paclitaxel alone in
SUM149 (P = 0.008; Figure 4B) and FC-IBC-02 (P = 0.001;
Figure 4D) models. Compared with AZD8931 alone, the
difference was marginally significant for SUM149 tumors
(P = 0.056) and FC-IBC-02 tumors (P = 0.07).
Finally, we examined the expression of total EGFR,
HER2, HER3, phosphorylated EGFR, phosphorylated
HER2, and phosphorylated HER3 in SUM149 xenografted
tumors by immunohistochemistry. As expected, high level
expression of EGFR and low levels of HER2 and HER3 ex-
pression were observed in both AZD8931-treated and
control tumors. The expression of phosphorylated EGFR,
HER2, and HER3 was inhibited in AZD8931-treated tu-
mors compared with control tumors (Figure 5A). The
average of pathologist’s H-score for both membrane and
cytoplasmic staining was shown in Figure 5B. Together,
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Figure 2 AZD8931 inhibits EGFR pathway protein expression. A. SUM149 cells were treated with vehicle control or 1 μmol/L AZD8931 for 4,
24, and 48 hrs. B. SUM149 and FC-IBC-02 cells were treated with 0 (vehicle), 0.01, 0.1, or 1 μmol/L AZD8931 for 24 hrs. Expression of EGFR, p-Akt,
Akt, and β-Actin was examined by immunoblot analysis.
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we conclude that AZD8931 significantly inhibits tumor
growth in HER2 non-amplified IBC xenograft models by
inhibiting EGFR, HER2 and HER3 phosphorylation. The
combination of paclitaxel + AZD8931 was more effective
than single agent paclitaxel or AZD8931 alone at delaying
tumor growth.
Discussion
In this study, we have shown that AZD8931 significantly
suppressed IBC cell growth in vitro and tumor growth
in vivo in two IBC cell lines including a new cell line-
FC-IBC-02 derived from pleural effusion of an IBC
patient. AZD8931 could have the potential to increase
the antitumor activity when used in combination with
chemotherapy.
EGFR can be overexpressed in all subtypes of breast
cancer, but it is more frequently overexpressed in basal-
like and triple-negative breast cancer including IBC
[17-19]. A recent study showed that TNIBC is associated
with poor overall survival and high locoregional relapse
[20]. EGFR-positive IBC was associated with a signifi-
cantly worse survival rate and increased risk of recur-
rence than EGFR-negative IBC [7,8]. There are several
specific inhibitors of EGFR including gefitinib, erlotinib
and cetuximab, and others have been studied for the
treatment of breast cancer including IBC in clinical trials
[21], but results so far remain controversial and disap-
pointing. However, EGFR remains an important target
for developing novel therapeutics because the options
for TNIBC treatment are very limited.
Previous studies have shown that AZD8931 was sig-
nificantly more potent in inhibiting cell growth in vitro
and tumor growth in vivo across different cell line models
including one human breast cancer cell line as compared
with gefitinib or lapatinib [16]. AZD8931 also significantly
affected EGFR, HER2, and HER3 phosphorylation and
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downstream signaling pathways, apoptosis, and prolifera-
tion. In the present study, we extended the previous study
to further evaluate the antitumor activity of AZD8931
alone or in combination with paclitaxel in preclinical
models of EGFR-overexpressed and HER2 non-amplified
IBC. The SUM149 cell line expresses high levels of EGFR
and is considered a representative IBC preclinical model,
in spite of the fact it was developed from patients with pri-
mary disease, who had not yet received neoadjuvant ther-
apy. The newly developed FC-IBC-02 cell line is a more
representative model for the IBC studies, particularly for
evaluating progression and metastasis, since the cell line
has been developed from a patient with advanced IBC.
FC-IBC-02 cells formed tumor spheroids and were able to
develop tumor with the presence of tumor emboli and
metastasis in SCID mice [14,15]. FC-IBC-02 cells ex-
pressed a high level of EGFR and relatively low levels of
total HER2 and HER2-HER3 heterodimers making an
ideal model to evaluate EGFR-targeting therapies. As ex-
pected, AZD8931 significantly inhibited cell proliferation
in vitro and tumor growth of IBC cells in vivo in ortho-
tropic xenografted models. Since FC-IBC-02 cells also
expressed an intermediate level of HER3, AZD8931 could
have potential to inhibit tumor growth through inactiva-
tion of HER2/HER3 and its downstream pathway. Previ-
ous study has shown that AZD8931 caused a significant
increase of apoptotic protein expression in xenografted tu-
mors [16]. Here, we showed a significant induction of
apoptotic cell death following AZD8931 treatment in vitro
in IBC cells.
Most significantly, in current IBC models, we showed
that AZD8931 monotherapy significantly inhibited tumor
growth and the combination of paclitaxel + AZD8931 re-
sulted in the highest levels of tumor growth inhibition
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Figure 4 AZD8931 inhibits the growth of SUM149 and FC-IBC-02 cells in vivo in SCID mice. SUM149 (A) and FC-IBC-02 (C) cells were
orthotopically transplanted into the mammary fat pads of SCID mice. Animals were randomized into groups (n = 5/group) when tumor volumes
were approximately 50–80 mm3. AZD8931 was given by oral gavage at doses of 25 mg/kg per day, 5 days/week for 4 weeks. Paclitaxel was given
twice weekly by subcutaneously injection at 10 mg/kg for 4 weeks. The mean tumor volumes were measured at the time points indicated. In
SUM149 xenografts (A), *P < 0.01 (vs. control), **P = 0.01 (vs. paclitaxel + AZD8931). In FC-IBC-02 xenografts (C), *P < 0.001 (vs. control), **P < 0.01
(vs. paclitaxel + AZD8931). SUM149 (B) and FC-IBC-02 (D), the size of tumors was measured by weights (mg) after tumors were removed from
mice at the end of experiments. The data shown represent the mean of tumor weights with SD. *P < 0.05 (vs. control); **P < 0.01 compared to
control. The combination of paclitaxel + AZD8931 compared with paclitaxel (P = 0.008, SUM149; P = 0.001, FC-IBC-02).
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in vivo in both cell lines (Figure 4). The most common
treatment for IBC is multimodal involving neoadjuvant
combination chemotherapy followed by surgery, adjuvant
chemotherapy, or radiotherapy [5]. Conventional chemo-
therapy regimens are not sufficient for the treatment of
IBC, particularly for TNIBC. Targeted therapy against
HER2 is one promising strategy for the treatment of IBC
patients with HER2 amplification. Several EGFR targeted
therapies including small molecule inhibitors and anti-
EGFR antibodies have been evaluated in preclinical and
clinical studies [21-25]. Patients with EGFR expressing tu-
mors did not respond to EGFR-targeted therapy, which
suggests that EGFR expression alone does not indicate
tumor cell growth dependence on the EGFR pathway.
One study indicated that the significant interactions be-
tween EGFR and other alternative signaling pathway ki-
nases, such as c-MET and IGF-1R are linked to resistance
to targeted therapies [26]. Thus, future studies are war-
ranted to consider combining of EGFR-targeted therapy
with drugs targeting other alternate signaling pathways to
improve efficacy. Several antibodies targeting EGFR have
also been investigated for their efficacy in patients with
TNBC, some results have showed the clinical benefit in
combination with chemotherapy drugs for patients with
TNBC [27,28].
Metastasis is the primary cause of breast cancer mor-
tality. IBC is characterized by locally advanced disease
and high rates of metastasis even after multimodality
treatments [29]. In IBC, inflammation is associated with
the invasion of aggregates of tumor cells defined as
tumor emboli, into the dermal lymphatics causing an
obstruction of the lymph channels [30]. Currently, the
molecular pathways driving the early development of
metastasis in IBC remain poorly characterized. EGFR
family and its downstream signaling pathways are known
to promote cell migration, angiogenesis, invasion, and
metastasis [22]. Previous studies have shown that the
EGFR inhibitor erlotinib (Tarceva™) significantly inhibited
Figure 5 AZD8931 inhibits EGFR pathway protein expression in vivo. A. Immunohistochemical analysis of EGFR, HER2, HER3, phospho-EGFR,
phospho-HER2, and phospho-HER3 in SUM149 xenografts following AZD8931 acute treatment (50 mg/kg/per day × 4 days). B. The average of
pathologist’s H-score for both membrane and cytoplasmic staining.
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cell motility, invasiveness, tumor growth, and spontan-
eous lung metastasis in EGFR-expressing IBC models
[31]. Further therapeutic studies are warranted to exam-
ine the effects of AZD8931 on the invasiveness and me-
tastasis of IBC.
Conclusions
We demonstrate that EGFR/HER2/HER3-targeting with
AZD8931 is associated with promising preclinical activ-
ity in EGFR-overexpressed and HER2 non-amplified IBC
models, suggesting an important novel therapeutic ap-
proach for this aggressive disease.
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